Search research articles
Contact Us
Filters
Showing results (61-70 of 100) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
March 13, 2018
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
Jordan Berlin, Ramesh K Ramanathan, John H Strickler, et al.
Molecular Cancer Therapeutics
|
July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Michael S Gordon, John Nemunaitis, Minal Barve, et al.
Targeted Oncology
|
January 5, 2021
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
Catherine H Watson, Gloria Broadwater, Janice Wong, et al.
The Oncologist
|
August 13, 2022
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
Michelle F Green, Catherine H Watson, Sarah Tait, et al.
Scientific Reports
|
March 24, 2026
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Andrew B Nixon, Fábio C P Navarro, Katherine I Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Annals of Surgical Oncology
|
July 9, 2025
Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annie Liu, Ellery H Reason, Brittany G Sullivan, et al.
Annals of Surgical Oncology
|
July 23, 2025
Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study
Ellery H Reason, Michael D Aiduk, Amanda L Nash, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States
Anivarya Kumar, Jennifer R Owen, Nicholette T Sloat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 100) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
March 13, 2018
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
Jordan Berlin, Ramesh K Ramanathan, John H Strickler, et al.
Molecular Cancer Therapeutics
|
July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Michael S Gordon, John Nemunaitis, Minal Barve, et al.
Targeted Oncology
|
January 5, 2021
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
Catherine H Watson, Gloria Broadwater, Janice Wong, et al.
The Oncologist
|
August 13, 2022
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
Michelle F Green, Catherine H Watson, Sarah Tait, et al.
Scientific Reports
|
March 24, 2026
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Andrew B Nixon, Fábio C P Navarro, Katherine I Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Annals of Surgical Oncology
|
July 9, 2025
Circulating Tumor DNA as a Novel Prognostic Biomarker of Therapeutic Efficacy in Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annie Liu, Ellery H Reason, Brittany G Sullivan, et al.
Annals of Surgical Oncology
|
July 23, 2025
Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study
Ellery H Reason, Michael D Aiduk, Amanda L Nash, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States
Anivarya Kumar, Jennifer R Owen, Nicholette T Sloat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Page
of 10